Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Azercabtagene Zapreleucel

Cell therapy (CAR-T) · Kills target cells, directed at CD19

Phase 1 Most advanced trial
1 Registered trials

What is Azercabtagene Zapreleucel?

Azercabtagene zapreleucel is an allogeneic, off-the-shelf T-lymphocyte cell therapy genetically modified to express a chimeric antigen receptor targeting CD19, a B-cell surface antigen. The modified cells are designed to recognize and kill CD19-expressing B cells. It is being studied in B-cell mediated autoimmune disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Therapy area
Immunology
In trials of
TGTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06680037 Phase 1 B-cell Mediated Autoimmune Disorders Recruiting TGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Mediated Autoimmune Disorders

Other drugs acting on CD19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.